<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Proteolytic enzymes have been implicated in driving <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> by means of their <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell microenvironment activity where they promote proliferation, differentiation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, migration, and invasion </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutic strategies have focused on attenuating their activity using small molecule inhibitors, but the association of proteases with the cell surface during <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> opens up the possibility of targeting these using antibody dependent cellular cytotoxicity (ADCC) </plain></SENT>
<SENT sid="2" pm="."><plain>Cathepsin S is a lysosomal cysteine protease that promotes the growth and invasion of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and endothelial cells during <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Our analysis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patient biopsies shows that cathepsin S associates with the cell membrane indicating a potential for ADCC targeting </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Here we report the cell surface characterization of cathepsin S and the development of a humanized antibody (Fsn0503h) with immune effector function and a stable in vivo half-life of 274 hours </plain></SENT>
<SENT sid="5" pm="."><plain>Cathepsin S is expressed on the surface of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells representative of colorectal and <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> (23%-79% positive expression) </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore the binding of Fsn0503h to surface associated cathepsin S results in natural killer (NK) cell targeted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> killing </plain></SENT>
<SENT sid="7" pm="."><plain>In a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> model Fsn0503h elicits a 22% cytotoxic effect </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This data highlights the potential to target cell surface associated enzymes, such as cathepsin S, as therapeutic targets using antibodies capable of elicitingADCC in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
</text></document>